THE TAPE

HCA Healthcare, Inc.

$511.78▲ +2.55%
Last close
Relative strength
76RS
of 99, against every stock▲ +11 on the month
Powering up
Unconfirmed
+20.8%
six months against the S&P 500
52-week range
−8.0%
from the high
$353.99$556.52
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +4% on a year ago
Why it is on no screen

HCA is off the screens on one check: a base has formed.

A base has formedNo pause of 3 weeks or more inside the last 24 weeks.
Long enough to countNeeds a base first.
Shallow enoughNeeds a base first.
Close to its pivotNeeds a base first.
Relative strengthRS 76 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$487.48
-4.7% · tested 5× · last 3 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

HCA Healthcare, Inc. is not on any of the screens right now. Its relative strength rating is 76, and it sits in General Medical & Surgical Hospitals.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+15.1%
Three months against the S&P 500
+28.9%
Six months against the S&P 500
+20.8%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
29
days
Ex-dividend in 29 days
Dec 15, 2026
  1. Ex-dividendconfirmedin 29d
    Ex-dividend date
    Dec 15, 2026
How it moves on earnings

On average 3.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$78.7B
+3.6% year on year
Operating margin
—
Net margin
8.6%
Free cash flow
$6.0B
5.6% of market cap
Price to sales
1.36×
Price to earnings
15.8×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 27
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$19.8B
-1.9% QoQ · +3.6% YoY
Gross margin
—
Net income
$1.6B
Positive
Free cash flow
$3.1B
Cash generating

What the numbers say

  • Revenue +3.6% year over year, -1.9% on the quarter
  • Good: Profitable: net income $1.58B
  • Good: Cash generating: operating cash flow $4.46B, free cash flow $3.10B
  • Good: Share count -8.0% in a year: buying back
  • Weak: Net debt $49.59B · cash $908M
Revenue by quarter
Free cash flow
Net income
shares -8.0% in a year · net debt $49.6B
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is the balance sheet: net debt $49.59B · cash $908M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-05
above 20d & 50d on 2.8x volume at 510.70
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-05
+10.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-05
5.1 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-29
above 20d & 50d on 1.6x volume at 463.22
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Reported resultsFiling · 2026-10-28
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-27
reports 2026-10-27 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Unusual volumeTape · 2026-09-19
13.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
10
$18,251,400 total

Sold: Rossitto Erica, Foster Jon M, Schlosser Michael J.

Not counted above: 11 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-10 Rossitto Erica · SVP & Chief Nurse Executivesell3,500$1,770,335
2026-11-06 Foster Jon M · EVP and COOsell890$444,084
2026-11-06 Foster Jon M · EVP and COOsell1,684$838,629
2026-11-06 Foster Jon M · EVP and COOsell1,066$529,717
2026-11-06 Foster Jon M · EVP and COOsell2,692$1,334,839
2026-11-06 Foster Jon M · EVP and COOsell7,595$3,758,876
2026-11-06 Foster Jon M · EVP and COOsell6,302$3,110,538
2026-11-06 Foster Jon M · EVP and COOsell1,484$730,101

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy1
Buy14
Hold9
Sell1
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
HCA Healthcare, Inc. (HCA) — The Tape